JPRN-jRCTc030210026招募中2 期
Dendritic cell therapy based on nepantigen-gene analysis - Neoantigen-loaded DC therapy
Tanigawa Keishi0 个研究点目标入组 30 人开始时间: 2021年4月9日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 12age old 至 <= 85age old（—）
- 性别
- All
入选标准
- •Patients must:
- •- have ECOG Performance Status for 0, 1 or 2.
- •- maintain adequate function of key organs when the eligibility is confirmed, in particular:
- •1. haemoglobin 8.0 g/dl or more
- •2. platelet 50.000 /mm3 or more
- •3. total bilirubin 3 x ULN or more
- •4. AST/ALT 3 x ULN or less
- •5. creatinine 3 x ULN or less
- •- provide written consent for treatment of neoantigens-loaded DC vaccination.
- •- have a proper mental condition and an ability to recognize the object and contents of the study when informed consent is obtained.
排除标准
- •Patients must not:
- •- be impossible to obtain blood sample by Leukapeheresis.
- •- be positive in HIV antibody test.
- •- have active auto-immune disorder.
- •- have serious underlying disease.
- •- be pregnant (including pregnancy seeker)
- •- be judged ineligibles by clinician in this trial.
研究者
相似试验
已完成
不适用
Dendritic cell-based immunotherapy for ovrian cancer patients.NeoplasmsKCT0000831Asan Medical Center10
尚未招募
不适用
Dendritic cell-based immunotherapy combined with low-dose cyclophosphamide in patients with malignant pleural mesotheliomamesothelioma10035597NL-OMON32554Erasmus MC, Universitair Medisch Centrum Rotterdam10
进行中（未招募）
1 期
Dendritic cell-based immunotherapy for advanced solid tumours of children and young adultsChildren and young adults with advanced solid tumours: relapsed or metastatic sarcomas or central nervous system tumours.EUCTR2013-003632-71-ESClínica Universidad de Navarra/Universidad de Navarra10
已完成
1 期
Dendritic cell-based tumor-specific immunotherapy against malignant brain tumor - Phase I clinical trialMalignant brain tumor (malignant glioma)JPRN-UMIN000000914Shizuoka Cancer Center12
未知
1 期
Dendritic cell therapy and intratumor dendritic cell injection therapy using Tumor associated antigen or tumor lysate for patients with advanced and recurrent canceradvanced and recurrent cancerJPRN-UMIN000000775Fukushima Medical University25